Manning Paul B's Form 4 filing
Taysha Gene Therapies, Inc. (TSHA) · filed Feb 4, 2022
- Accession no.
- 0001209191-22-007126
- Filed
- Feb 4, 2022
- Trade date
- Feb 2-3, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions and 0 derivative transactions. Open-market purchases total $1.57M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Manning Paul BCIK 0001494695 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 2, 2022 | Common Stock | PPurchaseAcquired | +58,000 | $7.77 | +$450,660 | 92,202 | Direct | |
| Feb 2, 2022 | Common Stock | PPurchaseAcquired | +45,000 | $7.77 | +$349,650 | 2,065,102 | Indirect | |
| Feb 2, 2022 | Common Stock | PPurchaseAcquired | +22,000 | $7.77 | +$170,940 | 22,000 | Indirect | |
| Feb 3, 2022 | Common Stock | PPurchaseAcquired | +50,000 | $7.84 | +$392,000 | 142,202 | Direct | |
| Feb 3, 2022 | Common Stock | PPurchaseAcquired | +26,602 | $7.84 | +$208,559.68 | 2,091,704 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.